Challenges to Defining a Role for Progesterone in Breast Cancer

Overview

Journal Steroids

Publisher Elsevier

Specialty Biochemistry

Date 2008 Feb 5

PMID 18243264

Citations 29

Authors

Carol A Lange

Affiliations

Soon will be listed here.

Abstract

Progesterone is an ovarian steroid hormone that is essential for normal breast development during puberty and in preparation for lactation. The actions of progesterone are primarily mediated by its high affinity receptors, including the classical progesterone receptor (PR) -A and -B isoforms, located in diverse tissues such as the brain where progesterone controls reproductive behavior, and the breast and reproductive organs. Progestins are frequently prescribed as contraceptives or to alleviate menopausal symptoms, wherein progestin is combined with estrogen as a means to block estrogen-induced endometrial growth. Estrogen is undisputed as a potent breast mitogen, and inhibitors of the estrogen receptor (ER) and estrogen producing enzymes (aromatases) are effective first-line cancer therapies. However, PR action in breast cancer remains controversial. Herein, we review existing evidence from in vitro and in vivo models, and discuss the challenges to defining a role for progesterone in breast cancer.

Citing Articles

Insulin-like growth factor binding protein-6 modulates proliferative antagonism in response to progesterone in breast cancer.

Lariz F, Botero P, Shoffstall I, Houston K Front Endocrinol (Lausanne). 2024; 15:1450648.

PMID: 39698031 PMC: 11652171. DOI: 10.3389/fendo.2024.1450648.

CmPn signaling networks in the tumorigenesis of breast cancer.

Renteria M, Belkin O, Jang D, Aickareth J, Bhalli M, Zhang J Front Endocrinol (Lausanne). 2022; 13:1013892.

PMID: 36246881 PMC: 9556883. DOI: 10.3389/fendo.2022.1013892.

Breast Cancer Risk with Progestin Subdermal Implants: A Challenge in Patients Counseling.

Mohammed G, Mousa N, Talaat I, Ibrahim H, Saber-Ayad M Front Endocrinol (Lausanne). 2022; 12:781066.

PMID: 34975755 PMC: 8719328. DOI: 10.3389/fendo.2021.781066.

Molecular Subtypes and Local-Regional Control of Breast Cancer.

Fragomeni S, Sciallis A, Jeruss J Surg Oncol Clin N Am. 2017; 27(1):95-120.

PMID: 29132568 PMC: 5715810. DOI: 10.1016/j.soc.2017.08.005.

Early pregnancy sex steroids during primiparous pregnancies and maternal breast cancer: a nested case-control study in the Northern Sweden Maternity Cohort.

Fortner R, Tolockiene E, Schock H, Oda H, Lakso H, Hallmans G Breast Cancer Res. 2017; 19(1):82.

PMID: 28720108 PMC: 5516370. DOI: 10.1186/s13058-017-0876-8.

References

Qiu M, Lange C . MAP kinases couple multiple functions of human progesterone receptors: degradation, transcriptional synergy, and nuclear association. J Steroid Biochem Mol Biol. 2003; 85(2-5):147-57. DOI: 10.1016/s0960-0760(03)00221-8. View

Alkarain A, Jordan R, Slingerland J . p27 deregulation in breast cancer: prognostic significance and implications for therapy. J Mammary Gland Biol Neoplasia. 2004; 9(1):67-80. DOI: 10.1023/B:JOMG.0000023589.00994.5e. View

Santen R, JENG M, Wang J, Song R, Masamura S, McPherson R . Adaptive hypersensitivity to estradiol: potential mechanism for secondary hormonal responses in breast cancer patients. J Steroid Biochem Mol Biol. 2002; 79(1-5):115-25. DOI: 10.1016/s0960-0760(01)00151-0. View

Poole A, Li Y, Kim Y, Lin S, Lee W, Lee E . Prevention of Brca1-mediated mammary tumorigenesis in mice by a progesterone antagonist. Science. 2006; 314(5804):1467-70. DOI: 10.1126/science.1130471. View

Migliaccio A, Piccolo D, Castoria G, Di Domenico M, Bilancio A, Lombardi M . Activation of the Src/p21ras/Erk pathway by progesterone receptor via cross-talk with estrogen receptor. EMBO J. 1998; 17(7):2008-18. PMC: 1170546. DOI: 10.1093/emboj/17.7.2008. View

Mulac-Jericevic B, Lydon J, DeMayo F, Conneely O . Defective mammary gland morphogenesis in mice lacking the progesterone receptor B isoform. Proc Natl Acad Sci U S A. 2003; 100(17):9744-9. PMC: 187836. DOI: 10.1073/pnas.1732707100. View

Kumar S, Walia V, Ray M, Elble R . p53 in breast cancer: mutation and countermeasures. Front Biosci. 2007; 12:4168-78. DOI: 10.2741/2378. View

Condon J, Hardy D, Kovaric K, Mendelson C . Up-regulation of the progesterone receptor (PR)-C isoform in laboring myometrium by activation of nuclear factor-kappaB may contribute to the onset of labor through inhibition of PR function. Mol Endocrinol. 2005; 20(4):764-75. DOI: 10.1210/me.2005-0242. View

Pierson-Mullany L, Lange C . Phosphorylation of progesterone receptor serine 400 mediates ligand-independent transcriptional activity in response to activation of cyclin-dependent protein kinase 2. Mol Cell Biol. 2004; 24(24):10542-57. PMC: 533997. DOI: 10.1128/MCB.24.24.10542-10557.2004. View

10.

Graham J, Clarke C . Physiological action of progesterone in target tissues. Endocr Rev. 1997; 18(4):502-19. DOI: 10.1210/edrv.18.4.0308. View

11.

McGowan E, Clarke C . Effect of overexpression of progesterone receptor A on endogenous progestin-sensitive endpoints in breast cancer cells. Mol Endocrinol. 1999; 13(10):1657-71. DOI: 10.1210/mend.13.10.0356. View

12.

Pratt W, Toft D . Regulation of signaling protein function and trafficking by the hsp90/hsp70-based chaperone machinery. Exp Biol Med (Maywood). 2003; 228(2):111-33. DOI: 10.1177/153537020322800201. View

13.

Stute P, Wood C, Kaplan J, Cline J . Cyclic changes in the mammary gland of cynomolgus macaques. Fertil Steril. 2004; 82 Suppl 3:1160-70. DOI: 10.1016/j.fertnstert.2004.04.035. View

14.

Robinson G, Hennighausen L, Johnson P . Side-branching in the mammary gland: the progesterone-Wnt connection. Genes Dev. 2000; 14(8):889-94. View

15.

Lange C, Gioeli D, Hammes S, Marker P . Integration of rapid signaling events with steroid hormone receptor action in breast and prostate cancer. Annu Rev Physiol. 2006; 69:171-99. DOI: 10.1146/annurev.physiol.69.031905.160319. View

16.

Gee J, Robertson J, Ellis I, Nicholson R . Phosphorylation of ERK1/2 mitogen-activated protein kinase is associated with poor response to anti-hormonal therapy and decreased patient survival in clinical breast cancer. Int J Cancer. 2001; 95(4):247-54. DOI: 10.1002/1097-0215(20010720)95:4<247::aid-ijc1042>3.0.co;2-s. View

17.

Rose-Hellekant T, Sandgren E . Transforming growth factor alpha- and c-myc-induced mammary carcinogenesis in transgenic mice. Oncogene. 2000; 19(8):1092-6. DOI: 10.1038/sj.onc.1203350. View

18.

Sakamoto K, Creamer B, Triplett A, Wagner K . The Janus kinase 2 is required for expression and nuclear accumulation of cyclin D1 in proliferating mammary epithelial cells. Mol Endocrinol. 2007; 21(8):1877-92. DOI: 10.1210/me.2006-0316. View

19.

Feng Y, Manka D, Wagner K, Khan S . Estrogen receptor-alpha expression in the mammary epithelium is required for ductal and alveolar morphogenesis in mice. Proc Natl Acad Sci U S A. 2007; 104(37):14718-23. PMC: 1976199. DOI: 10.1073/pnas.0706933104. View

20.

Dabrosin C . Increase of free insulin-like growth factor-1 in normal human breast in vivo late in the menstrual cycle. Breast Cancer Res Treat. 2003; 80(2):193-8. DOI: 10.1023/A:1024575103524. View